Professional
Added to YB: 2024-11-27
Pitch date: 2024-11-11
NTLA [bullish]
Intellia Therapeutics, Inc.
-27.87%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Market Cap
$2.0B
Pitch Price
$17.15
Price Target
85.00 (+587%)
Dividend
N/A
EV/EBITDA
-4.35
P/E
-3.98
EV/Sales
22.97
Sector
Biotechnology
Category
growth
Show full summary:
Intellia Therapeutics, Inc.: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors
NTLA: Early-stage gene editing pipeline progressing. FV $85. NTLA-2002 Phase 3 for HAE (35% approval prob), potential 2028 launch. NTLA-2001 Phase 3 for ATTR (40% prob), possible 2026 launch, $1B sales by 2034. $944M cash runway to late 2026. High R&D costs near-term.
Read full article (11 min)